Close Menu

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – Myeloma Health's parent company Signal Genetics said today that Pronto Diagnostics will distribute the Signal Myeloma Prognostic Risk Signature (MyPRS) test in Israel, under an exclusive agreement.

Tel Aviv-based Pronto provides molecular diagnostics-based oncology disease tests and genetic test kits, and it serves as a distributor for Pathwork Diagnostics and Epigenomics.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Associated Press reports that a state board in Texas has asked ANDE, a maker of rapid DNA machines, to halt its work there.

James Wyngaarden, the former director of the US National Institutes of Health, has died at 94, according to Duke University School of Medicine.

Researchers find that a 30-year-old skull comes from a narwhal-beluga hybrid, according to Science News.

In Nature this week: study of value diversity in GWAS, Epstein-Barr virus subtypes linked to nasopharyngeal carcinoma risk, and more.

Jul
23
Sponsored by
Qiagen

This webinar will discuss how the Molecular Pathology Laboratory at the University of Oklahoma (OUMP) is using a new quality improvement model to support molecular testing of oncology patients. 

Jul
24
Sponsored by
Hologic

This webinar will share the results of comparisons of commercially available nucleic acid amplification tests for use in routine screening of pregnant women for Group B Streptococcus (GBS).

Jul
30
Sponsored by
Mission Bio

This webinar will outline a project that performs large-scale and integrative single-cell genome and transcriptome profiling of pediatric acute lymphoblastic leukemia (ALL) cases at diagnosis, during drug treatment, and in case of relapse.